total knee arthroplasty
Conditions
Interventions
F1 group:Administration of 0.25% ropivacaine for continuous femoral nerve analgesia, total dose 300 ml. Continuous infusion 4 ml/h, bolus dose 5 ml/ml, lock time 15 min
F2 group:Administration of 0.25% ropivacaine + 20ug/ml hydromorphone for continuous femoral nerve analgesia, total dose 300 ml. Continuous infusion 4 ml/h, bolus dose 5 ml/ml, lock time 15 min
Sponsors
Peking University, Shougang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Informed consent of the patient and approval of the hospital ethics committee; Selective total knee arthroplasty under intraspinal anesthesia and postoperative analgesia; Age 18-80; ASA grade I~III; BMI18-35kg/?.
Exclusion criteria
Exclusion criteria: Patients do not agree or voluntarily withdraw from the study; History of knee joint trauma, surgery, malignant tumor, primary disease of lower limb nerve or muscle; Serious basic diseases, such as dysfunction of heart, liver, lung, kidney, brain and other organs and abnormal coagulation function;History of mental illness; Having cognitive impairment and unable to complete the pain score of VAS; Contraindication of intraspinal anesthesia; People who are allergic to any of the drugs used in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS pain score (RVAS) at rest at 6h, 24h, 48h and 72h after surgery;Passive activity VAS pain score (PVAS) at 6h, 24h, 48h and 72h after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quadriceps muscle strength;Joint flexion;TUG score;Tinetti score;C-reactive protein;interleukin-6;procalcitonin; | — |
Countries
China
Contacts
Public ContactWang Ye
Peking University, Shougang Hospital
Outcome results
None listed